Come ridurre il rischio cardiovascolare attraverso il controllo del metabolismo calcio fosforo nell'uremico in dialisi,nel Terzo Millennio?

Ganesh S.K. , Stack A.G. , Levin N.W. , Hulbert-Shearon T. , Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Am Soc Nephrol 2001; 12: 2131–8.

Block G.A. , Klassen P.S. , Lazarus J.M. , Ofsthun N. , Lowrie E.G. , Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–18.

Kalantar-Zadeh K. , Kuwae N. , Regidor D.L. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771–80.

Go A.S. , Chertow G.M. , Fan D. , McCulloch C.E. , Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.

Foley R.N. , Parfrey P.S. , Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(suppl): S112–9.

Marco M.P. , Craver L. , Betriu A. , Belart M. , Fibla J. , Fernàndez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 2003; 85(suppl): S111–4.

Tentori F. , Hunt W.C. , Rohrscheib M. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18: 2377–84.

Spiegel D.M. , Raggi P. , Smits G. , Block G.A. Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant 2007; 21: [Epub ahead of print]

Neves K.R. , Graciolli F.G. , dos Reis L.M.L. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262–70.

Dussol B. , Morand P. , Martinat C. , Lombard E. , Portugal H. , Brunet P. , Berland Y. Influence of parathyroidectomy on mortality in hemodialysis patients: a prospective observational study. Ren Fail 2007; 29: 579–86.

Schlosser K. , Veit J.A. , Witte S. Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial. Trials 2007; 8: 22.

Martin K.J. , Gonzalez E.A. , Gellens M. , Hamm L.L. , Abboud H. , Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427–32.

Sprague S.M. , Llach F. , Amdahl M. , Taccetta C. , Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483–90.

Chertow G.M. , Blumenthal S. , Turner S. , Roppolo M. , Stern L. , Chi E.M. , Reed J ; CONTROL Investigators. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1: 305–12.

Teng M. , Wolf M. , Lowrie E. , Ofsthun N. , Lazarus J.M. , Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446–56.

Teng M. , Wolf M. , Ofsthun M.N. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25.

Block G.A. , Martin K.J. , de Francisco A.L. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516–25.

Moe S.M. , Chertow G.M. , Coburn J.W. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760–71.

Cunningham J. , Danese M. , Olson K. , Klassen P. , Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–800.

Foley R.N. , Parfrey P.S. , Harnett J.D. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16: 386–93.

Slinin Y. , Foley R.N. , Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788–93.

Blacher J. , Guerin A.P. , Pannier B. , Marchais S.J. , London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938–42.

London G.M. , Guérin A.P. , Marchais S.J. , Métivier F. , Pannier B. , Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731–40.

Chertow G.M. , Burke S.K. , Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245–52.

Collins A.J. , St Peter W.L. , Dalleska F.W. , Ebben J.P. , Ma J.Z. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000; 54: 334–41.

Suki W.N. , Zabaneh R. , Cangiano J.L. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130–7.

Tonelli M. , Wiebe N. , Culleton B. , Lee H. , Klarenbach S. , Shrive F. , Manns B ; for the Alberta Kidney Disease Net-work. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856–66.

Tentori F. , Hunt W.C. , Stidley C.A. , Rohrscheib M.R. , Bedrick E.J. , Meyer K.B. , Johnson H.K. , Zager PG ; Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858–65.

London G.M. , Guérin A.P. , Verbeke F.H. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613–20.

Evaluation of cinacalcet HCl therapy to lower cardiovascular events (Evolve) trial. ClinicalTrial.gov identifier NCT0034589.